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Abstract
Background Drug-coated balloons (DCBs) have been
developed for the percutaneous treatment of coronary
artery disease. An initial focus has been the management of
in-stent restenosis (ISR) but randomised controlled trials
(RCTs) have been small and powered only for angio-
graphic endpoints.
Objective The aim of the work was to assess the clinical
and angiographic outcomes of patients treated for ISR with
DCB versus control (balloon angioplasty or drug-eluting
stents) by a meta-analysis of RCTs.
Methods A comprehensive search was performed of
RCTs where patients with ISR were randomly assigned to
either DCB or alternative coronary intervention. Outcome
measurements were death, myocardial infarction (MI),
target lesion revascularisation (TLR), binary definition of
restenosis and in-lesion late luminal loss (LLL).
Results Four studies were identified that fulfilled the
inclusion criteria. Pooled odds ratios (ORs) were calculated
for patients treated for ISR (n = 399). Mean follow-up
duration was 14.5 months. DCBs were associated with
lower rates of TLR [8.8 vs. 29.7 % OR (95 % confidence
interval, CI) 0.20 (0.11–0.36), p \ 0.0001], binary reste-
nosis [10.3 vs. 41.3 % OR (95 % CI) 0.13 (0.07–0.24),
p \ 0.00001] and MI [0.5 vs. 3.8 %, OR (95 % CI) 0.21
(0.04–1.00), p = 0.05]. No significant heterogeneity was
identified.
Conclusion Drug-coated balloons appear to be effective
versus control in reducing TLR and possibly MI versus
balloon angioplasty or drug-eluting stents in the manage-
ment of ISR.
Keywords Coronary artery disease  Angioplasty 
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MD Mean difference
MI Myocardial infarction
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POBA Balloon angioplasty
PACCOCATH ISR Treatment of coronary in-stent
restenosis with a catheter
PCI Percutaneous coronary intervention
PEPCAD II Paclitaxel-coated balloon catheter
versus paclitaxel-coated stent for the
treatment of coronary in-stent
restenosis
PEPCAD DES Prospective randomized trial of a
paclitaxel-coated balloon vs.
uncoated balloon angioplasty in
patients with drug-eluting stent
restenosis
PEPPER Paclitaxel releasing balloon in
patients presenting with in-stent
restenosis
RCT Randomised controlled trial
TLR Target lesion revascularisation
Introduction
Several drug-coated balloons (DCBs) have been devel-
oped for the percutaneous treatment of coronary artery
disease. They are all coated with the anti-proliferative
drug paclitaxel with or without a carrier that influence not
only drug solubility but also drug transfer and biological
efficacy. In practise, the DCB is inflated within the cor-
onary artery, with direct drug delivery to the coronary
endothelium [1]. The aim of local drug delivery is to
inhibit neo-intimal hyperplasia and promote rapid healing
of the treated vessel. In comparison with drug eluting
stents (DES), the current gold standard strategy for
percutaneous coronary intervention (PCI), DCBs have
theoretical benefits that include more uniform drug dis-
tribution at higher doses, no permanent vascular scaffold
left in situ and no need for a polymer. These features
allow for shorter durations of dual anti-platelet therapy
and may eliminate some of the stimuli that predispose to
stent thrombosis [1, 2].
With the widespread successful application of DES
[3], it is not currently clear where DCBs may provide
additional benefits. Restenosis within previously implan-
ted bare-metal stents (BMS) or DES is considered a
possible indication for DCB therapy [4]. Several ran-
domised controlled trials (RCTs) have been performed,
but they have been small and powered for angiographic
endpoints.
The goal of this meta-analysis was to determine the role
of DCB in the management of in-stent restenosis (ISR).
Methods
The present meta-analysis was performed according to the
established methods of Cochrane Guidelines [5] and in
compliance with the PRISMA statement [6] for reporting
systematic reviews and meta-analyses in health care
interventions.
Study eligibility and search strategy
Studies were eligible for inclusion if patients were ran-
domly assigned to either DCB or an alternative coronary
intervention, with appropriate reporting of methodologies,
baseline patient and procedural data and clinical events at
least 6 months following the index procedure. Published
manuscripts and adequately reported oral abstracts were
considered for inclusion to minimise the risk of publication
bias. No language barrier was applied. Medline, Embase,
and Cochrane databases were searched, as well as the web-
based resources, ‘clinicaltrials.gov’ and Google Scholar.
Search terms were ‘‘drug eluting balloon’’, ‘‘drug coated
balloon’’, ‘‘paclitaxel eluting balloon’’, ‘‘randomised con-
trolled trial’’, ‘‘controlled clinical trial’’, ‘‘double-blind’’,
‘‘placebo’’, and ‘‘random’’. Where unpublished RCTs were
identified, Scientific Sessions of the American College of
Cardiology [http://www.acc.org], American Heart Associ-
ation [http://www.aha.org], European Society of Cardiology
[http://www.escardio.org], Transcatheter Cardiovascular
Therapeutics [http://www.tctmd.com] and EuroPCR [http://
www.europcr.com] websites were searched. The literature
searches were performed independently by two authors.
Titles and abstracts were reviewed to determine appropri-
ateness for further review. Full texts of studies of potential
interest were then retrieved. Only studies of restenosis were
included in this meta-analysis.
Clinical outcomes and definitions
Data were extracted on baseline variables and on clinical
and angiographic outcomes. Outcomes of interest defined a
priori were all-cause mortality, myocardial infarction (MI,
defined according to each study protocol), target lesion
revascularisation (TLR, defined as re-intervention on the
index treated lesion), binary restenosis (defined as C50 %
luminal diameter stenosis by quantitative coronary angi-
ography), and in-lesion late luminal loss (LLL). LLL was
the difference between the in-segment minimal lumen
diameter after the procedure and at angiographic follow-up,
as evaluated by quantitative coronary angiography.
280 Clin Res Cardiol (2013) 102:279–287
123
Statistical analysis
Odds ratio (OR) and 95 % confidence interval (95 % CI)
were used as summary statistics for binary data, whereas
mean difference (MD) was used for continuous data. Het-
erogeneity was assessed by Cochran’s Q test, with a
2-tailed p = 0.1. The statistical inconsistency test (I2)
{[(Q-df)/Q] 9 100 %, where Q is the chi-squared statistic
and df its degrees of freedom} was also employed to
overcome the low statistical power of Cochran’s Q test.
Pooled ORs were calculated using a Fixed Effect Model
with the Mantel–Haenszel method. The DerSimonian and
Laird Random Effects Model was used in case of signifi-
cant heterogeneity and/or moderate or significant incon-
sistency ([50 %) across studies. The potential publication
bias was examined by constructing a ‘funnel plot’, in which
the standard error (SE) of the ln OR was plotted against the
OR of the chosen outcome. Finally, we addressed the
influence of each study by testing whether, deleting each in
turn, would have changed significantly the pooled results of
the meta-analysis (sensitivity analysis). Review Manager
5.1 (The Nordic Cochrane Center, Købehvn, Denmark) and
SPSS for Windows version 15 (SPSS, Chicago, Illinois)
were used for statistical computations.
Results
Literature search
The initial search identified 897 studies of potential rele-
vance. After assessment of title and abstract, 17 studies
were reviewed in full text for eligibility (Fig. 1). Two
further studies were identified through review of full text
articles. Eight studies were reviewed in full text but not
included because they were non-randomised registry
studies or case series [7–14]. Further RCTs that focused on
different aspects of de novo disease (e.g., bifurcation, MI,
small vessels) were also excluded [15–19]. The RCT
PACCOCATH I was initially reported at 1-year follow-up
[20], but was excluded in favour of the combined PAC-
COCATH I and II study [21] which had identical protocols
and were jointly reported at 2-year follow-up. Thus, four
studies were considered eligible for inclusion in the meta-
analysis [21–24]. The internal validity of the included
studies was appraised by two unblinded reviewers.
Baseline study characteristics
The studies included in the meta-analysis are summarised
in Table 1. Four studies compared DCBs with either con-
ventional balloon angioplasty (POBA) or DES in the
treatment of restenosis [21–24]. Three studies used Sequent
Please (B. Braun, Melsungen, Germany) [22–24] and one
used Paccocath (Bayer Schering Pharma, Berlin, Germany)
[21]; both balloons have the same carrier matrix and are
coated with 3 lg paclitaxel. Studies were multi-centre in
three cases and single centre in one. One study was double-
blind, two were single-blind, and one was unblinded. In
total, clinical follow-up was available for all 399 patients
enroled in the studies of ISR, with angiographic follow-up
available for 355 patients (89.0 %). The mean duration of
follow-up was 14.5 months.
Mortality
The odds ratios (ORs) for mortality in the RCTs of ISR are
shown in Fig. 2. There were a total of 16 deaths (Table 2).
Fig. 1 Study flow chart
Clin Res Cardiol (2013) 102:279–287 281
123
Mortality rates were numerically lower in DCB-treated
patients than in controls with a trend towards statistical
significance: the incidence of death was 5/217 (2.3 %) in
the DCB group and 11/182 (7.6 %) in the control group
[OR (95 % CI) 0.36 (0.12–1.02), p = 0.06], as shown in
Fig. 2.
Myocardial infarction
Among the studies of ISR, fewer MIs occurred in the DCB-
treated group (Table 2). This finding was of borderline
statistical significance: 1/217 (0.5 %) patients in the DCB
group and 7/182 (3.8 %) in the control group sustained an
MI [OR (95 % CI) 0.21 (0.04–1.00), p = 0.05). Figure 3
shows the individual and overall ORs for MI.
Target lesion revascularisation
When compared with controls, DCB use was associated
with significantly reduced TLR rates in patients treated for
ISR (Table 2): 19/217 (8.8 %) versus 54/182 (29.7 %) [OR
(95 % CI)] 0.20 (0.11–0.36), p \ 0.0001, Fig. 4).
Binary restenosis and late lumen loss
As shown in Table 3, the rate of binary restenosis was
reduced with the DCB strategy as compared to controls:
20/193 (10.3 %) versus 18/162 (41.3 %). Figure 5 dem-
onstrates that binary restenosis was significantly reduced in
DCB-treated patients [OR (95 % CI) 0.13 (0.07–0.24),
p \ 0.00001]. Mean in-stent LLL in the DCB group was
0.23 versus 0.75 mm in the control group (Table 3).
Patients treated with DCB had significantly less in-stent
LLL than patients receiving control [MD (95 % CI) -0.50
(-0.71; -0.30) mm, p \ 0.00001, Fig. 6).
Sensitivity analysis
Sensitivity analysis, performed by removing each of the
studies one at a time, demonstrated that no single study
influenced the overall results. Sensitivity analysis, per-
formed by including each of the studies one at a time
according to different length of follow-up, from the lowest
to the highest, showed that different follow-up times did
not influence the overall results.
Test for interaction
The interaction test showed no significant difference in
TLR results when DCB treatment was compared to control
patients treated with either POBA [21, 22, 24] or DES [23]
(v2 = 0.54, df = 1, p = 0.46).T
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Fig. 2 Meta-analysis for
mortality in in-stent restenosis
for DCB versus control;
individual and overall odds
ratios of mortality after
treatment with DCB or control
PCI are reported
Table 2 Summary of clinical outcomes in drug-eluting balloon randomised controlled trials
Study Follow-up (months) Patients at follow-up Death (n) MI (n) TLR (n)
DCB Control DCB Control DCB Control DCB Control
Habara et al. [19] 6 25 25 0 0 0 0 1 10
PACCOCATH ISR I AND II [18] 24 54 54 2 3 1 5 3 20
PEPCAD II ISR [20] 12 66 65 2 3 0 1 4 10
PEPCAD-DES [23] 12 72 38 1 5 0 1 11 14
Overall 217 182 5 11 1 7 19 54
Fig. 3 Meta-analysis for
myocardial infarction in in-stent
restenosis for DCB versus
control; individual and overall
odds ratios of incident
myocardial infarction after
treatment with DCB or control
PCI are reported
Fig. 4 Meta-analysis for target
lesion revascularisation in-stent
restenosis for DCB versus
control: individual and overall
odds ratios of target lesion
revascularisation after treatment
with DCB or control PCI are
reported
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Publication bias
The funnel plot for mortality did not show asymmetry by
visual inspection suggesting no publication bias (Fig. 7);
similarly, Egger’s test was not significant, thus excluding
the presence of publication bias; the same results were
observed for all the chosen outcomes.
Number needed to treat
The absolute difference in event rates results in five
patients needed to treat to prevent one TLR, and three
patients to prevent one binary restenosis (Fig. 8).
Discussion
The present meta-analysis demonstrates that the use of
DCB in the management of ISR is associated with
reduction in the incidence of binary restenosis, in-stent
LLL, TLR and possibly MI compared with controls (bal-
loon angioplasty or drug eluting stent).
In the United States, DCBs are not currently approved by
the regulatory authorities. However, DCBs have a class IIa,
level of evidence B indication in the ESC revascularisation
guidelines for the management of ISR in bare-metal stent.
Recruiting large patient numbers to RCTs for ISR is diffi-
cult; as such, individual studies included were relatively
small. Meta-analyses in these circumstances are particularly
useful. By pooling existing data, this study has provided
more robust clinical evidence for a broader group of
patients including restenosis of previously implanted DES.
Management of in-stent restenosis
In-stent restenosis has been reduced but not eliminated by
the use of DES. Indeed, given the numbers of more complex
interventions with DES, ISR will remain a prevalent clinical
Table 3 Summary of angiographic outcomes in drug-eluting balloon randomised controlled trials
Study Angiographic follow-up (n) Binary restenosis Late luminal loss
DCB Control DCB Control DCB Control
Habara et al. [19] 23 24 2 15 0.17 ± 0.45 0.72 ± 0.56
PACCOCATH ISR I AND II [18] 49 48 3 24 0.14 ± 0.46 0.81 ± 0.79
PEPCAD II ISR [20] 57 59 4 10 0.19 ± 0.39 0.45 ± 0.68
PEPCAD-DES [23] 64 31 11 18 0.43 ± 0.61 1.03 ± 0.77
Overall 193 162 20 67 0.23 0.75
Fig. 5 Meta-analysis for
binary restenosis in in-stent
restenosis for DCB versus
control; individual and overall
odds ratios of binary restenosis
after treatment with DCB or
control PCI are reported
Fig. 6 Meta-analysis for in-
stent/lesion late luminal loss in
in-stent restenosis for DCB
versus control; individual and
overall means and standard
deviations of in-stent/lesion late
luminal loss after treatment with
DCB or control PCI are reported
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presentation and on-going challenge for interventional car-
diologists. Current percutaneous treatment options for ISR
include treatment with balloon angioplasty (with or without
cutting balloons) and the placement of a second (drug-
eluting) stent. Vascular brachytherapy has previously been
advocated, but is not currently in widespread use. In studies
using implantation of a second DES, further re-intervention
rates remain high [25]. Thus, there is scope for improved and
expanded treatment options in this patient group.
Drug-coated balloons have been studied versus POBA
or DES in RCTs of stable patients presenting with reste-
nosis of either a BMS or DES [21–24]. DCB included in
the analysis were similar technologies; both balloons have
the same carrier matrix and are coated with 3 lg paclitaxel.
Overall, less LLL and lower rates of binary restenosis were
observed with DCB versus control. The pooled estimates
also demonstrated a significant reduction in re-intervention
on the target lesion when patients were treated with
DCB. Studies included reported clinical follow-up between
6 and 24 months. More recently the PACCOCATH studies
showed a durable benefit to 5 years in DCB-treated
patients [26].
In the three studies where DCBs were compared with
POBA [21, 22, 24], the MD in LLL was remarkably con-
sistent. A single study, PEPCAD II ISR, that compared
DCB with a DES (Taxus liberte¯), showed a trend in favour
of DCB but did not achieve statistical significance for a
reduction in clinical TLR [23]. Further comparisons with
newer generation DES would give additional useful
information. PEPCAD II ISR, however, did contribute to
the overall impression of superiority for DCB over alter-
native treatments, with a significant reduction in LLL and
numerically fewer binary restenosis and TLR [23]. Fur-
thermore, no interaction with type of control with respect
to TLR was demonstrated in the present analysis.
In the management of restenosis, DCBs have the prac-
tical advantage of not placing a further layer of metal
within a coronary artery and requiring shorter durations of
dual anti-platelet therapy. The results of the analysis were
consistent, with no evidence of statistical heterogeneity.
Therefore, DCBs appear to be an effective choice in the
management of ISR.
Perhaps more surprisingly, borderline significant
(p = 0.05) lower rates of MI were also observed for DCB
over controls (1/217 vs. 7/182). The absolute MI rate in this
meta-analysis was small, with 8/399 patients reporting an
MI. This finding was mainly powered by the PACCO-
CATH ISR I and II that reported follow-up data at 2 years
[21]. A potential explanation for this small but significant
absolute difference is that restenosis in itself can manifest
as MI. This proportion was estimated at 3.5 % (death or
MI) in the TAXUS clinical trials of de novo coronary
artery disease, although in unselected practise this has been
estimated up to 9.5 % [27, 28]. Based on DES versus BMS
RCTs, it has been hypothesised that reducing restenosis can
‘‘offset’’ the impact of late stent thrombosis on the end
points of MI and death [27]. Given that no stent thrombosis
was recorded, it is possible that DCBs provide the benefit
of a reduction in MI by attenuating binary restenosis and
LLL, without ‘‘trade-off’’ in this subgroup. More detailed
information on the timing of MI in relation to TLR, and a
greater number of studied patients and clinical events
would be required to confirm this finding and explanation.
Limitations
In general, the RCTs were well reported and the data were
easily abstracted from the published manuscripts. It is
recognised as a limitation that the three of the included
RCTs were either unblinded [23], or single blind [22, 24].
In addition, the meta-analysis would have been strength-
ened by the existence of more studies employing DES
control.
Many of the included RCTs allowed angiographic
rather than purely clinical driven revascularisation of target
Fig. 7 Funnel plot for the mortality outcome. The sample size of
each study (measured as standard error of the treatment effect) was
plotted against the odds ratio for overall mortality
Fig. 8 Absolute differences in rates of target lesion revascularisation
(TLR) and binary restenosis after treatment with DCB or control PCI
for in-stent restenosis
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lesions. RCTs are known in other fields to increase the
frequency of TLR clinical end points by the ‘‘oculo-ste-
notic’’ reflex. It is possible, therefore, that some cases of
TLR would not have occurred had protocol angiography
not been performed. This limitation in directly applying
these research findings to real world clinical practise is
mitigated by the important information gained by quanti-
tative angiography in these experimental circumstances.
We opted in this meta-analysis to focus on studies of
ISR. This approach has the advantage of comparing treat-
ment in a defined lesion pathology, with studies of similar
DCB. It was therefore considered valid to calculate pooled
estimates for these studies. However, it could be seen as a
limitation that we excluded studies of de novo disease from
the current analysis. DCB devices used in some de novo
lesion studies have varied significantly in their design to
current devices (e.g., no carrier molecule, ‘‘DCB-facili-
tated’’ BMS), which in some cases have not been made
available for use due to lack of efficacy [16, 29]. Further-
more, for those remaining DCB tested in RCTs, both the
patient sub-groups (e.g. AMI, stable angina), and com-
parator stents (e.g. DES, EPC capture stents) were incon-
gruent, rendering a comparison limited at best [17]. Thus, it
was concluded that a fair comparison is not currently
possible. DCBs remain in a developmental stage in de novo
disease, and further RCTs are awaited.
Finally, a limitation of this meta-analysis, common to all
the meta-analyses based on study-level data, is the lack of
individual patient data that would have further improved
the results. However, an in-depth robust statistical analysis
in the present study revealed no heterogeneity or publica-
tion bias. Further, given our study does not contain patient
level data, it is not possible to determine if there were
differences in the degree of angina pectoris and dyspnoea
before and following DCB treatment.
Conclusion
Drug-coated balloons appear effective versus controls
(balloon angioplasty or DES) in improving angiographic
outcomes, reducing TLR and possibly MI when used in the
management of restenosis of previously implanted stents.
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